Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept biosimilar - Alphamab

Next Previous
Search
Drug Profile

Belatacept biosimilar - Alphamab

Alternative Names: KN-019

Latest Information Update: 06 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Jiangsu Alphamab Biopharmaceuticals
  • Class Antirheumatics; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 25 Jul 2022 Phase II development is ongoing in China (Jiangsu Alphamab Biopharmaceuticals pipeline, July 2022)
  • 05 May 2022 Belatacept biosimilar - Alphamab is available for licensing as of 05 May 2022. https://www.alphamabonc.com/en/company/partnering.html
  • 05 May 2022 Alphamab plans to initiate a phase III registration trial in 2022 Q4

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top